Core Viewpoint - The controlled nuclear fusion sector is experiencing significant growth, driven by recent advancements and investments in fusion technology, particularly highlighted by the completion of the world's largest superconducting magnet system by the ITER organization [3]. Group 1: Market Performance - On May 6, the controlled nuclear fusion sector saw strong performance, with stocks such as Jiusheng Electric rising by 20%, and companies like Hailu Heavy Industry, Xue Ren Co., and others also experiencing significant gains [1]. - Notable stock performances included: - Heguang Intelligent: +10.00% with a market cap of 5.33 billion - Jiusheng Electric: +19.97% with a market cap of 3.46 billion - Other companies also reported gains exceeding 10% [2]. Group 2: Industry Developments - The ITER project, a major international collaboration involving multiple countries, aims to explore the commercial viability of controlled nuclear fusion technology, marking a significant milestone in the field [3]. - There is a growing trend of collaboration between leading IT and transportation companies with nuclear energy firms to develop small reactors for powering data centers and other applications [3]. Group 3: Institutional Insights - The nuclear fusion sector is recognized as a burgeoning industry, with increasing government support and capital investment, attracting long-term investments from major companies like Amazon and Microsoft [4]. - The Tokamak nuclear fusion market is projected to reach 681 billion by 2025-2030, with potential growth to 3 trillion by 2030-2035 as commercial reactors become operational [4]. - In China, nuclear power equipment investment is expected to grow from 25.7 billion in 2023 to a peak of 87.5 billion by 2028, indicating a compound annual growth rate (CAGR) of 26.91% [4].

Group 1 - Enwei Pharmaceutical reported a revenue of 196 million yuan in Q1 2025, a year-on-year increase of 7.1%, and a net profit attributable to shareholders of 14.62 million yuan, up 118.93% year-on-year [1] - The growth in Q1 2025 is attributed to the acquisition of Henan Xinxin Pharmaceutical, with the first batch of key products launched at the end of 2024 contributing to market growth [1] - The company plans to launch over 20 products in four batches from Q2 to Q3 2025, including significant products like Jian'er Pills and Wujihuai Feng Pills, which are expected to enhance revenue and profit [1] Group 2 - Enwei Pharmaceutical has operated the "Jie'er Yin" brand for 39 years, developing a comprehensive product matrix that includes various forms of Jie'er Yin products [2] - The Jie'er Yin series has sold over 700 million bottles, with the core product, Jie'er Yin Wash, consistently ranking first in the market share of gynecological traditional Chinese medicine in urban retail pharmacies [2] - The company plans to distribute a cash dividend of 1.8 yuan per 10 shares, totaling approximately 18.19 million yuan, to enhance shareholder returns [2] Group 3 - The company aims to improve product quality and user experience through process and packaging enhancements while focusing on the market strategy for Henan Xinxin Pharmaceutical's product launches [3] - Enwei Pharmaceutical has established advantages in the gynecological product sector, with a growing market size driven by increased health awareness among women [3] - The company is also expanding its market efforts in pediatric and respiratory medications, aiming for sustainable growth in the healthcare market through diversified business strategies and continuous innovation [3]

证券代码：301331 证券简称：恩威医药 公告编号：2025-021 恩威医药股份有限公司 关于一致行动人股份增持计划期限过半的进展公告 公司控股股东一致行动人成都杰威企业管理有限公司保证向本 公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述 或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露义务 人提供的信息一致。 特别提示： 1、恩威医药股份有限公司（以下简称"公司"）控股股东成都恩威投资（集 团）有限公司（以下简称"恩威集团"）一致行动人成都杰威企业管理有限公司 （以下简称"成都杰威/增持主体"）于 2025 年 1 月 21 日披露了《关于一致行动 人取得金融机构增持贷款承诺暨增持公司股份计划的公告》（公告编号： 2025-002），基于对公司未来持续稳定发展的信心和长期投资价值的认可，为增 强投资者信心，成都杰威计划自本公告之日起 6 个月内，通过集中竞价的方式增 持公司 A 股股份。总体增持金额不低于人民币 3,600 万元，不超过人民币 7,200 万元。 2、截至本公告披露日，本次增持计划实施期限已过半。2025 年 1 月 21 日 至 2025 年 4 月 20 日期间 ...

Fundraising Overview - The company raised a total of RMB 522.69 million through the issuance of 17,540,000 shares at a price of RMB 29.80 per share, with a net amount of RMB 442.95 million after deducting issuance costs [2][3] - Prior to the funds being in place, the company had already invested RMB 156.71 million from self-raised funds into projects and paid RMB 20.53 million in issuance costs [3] - As of December 31, 2023, the company had accumulated interest income and cash management product returns of RMB 5.48 million, with a total of RMB 169.18 million remaining in the fundraising account [4] Fund Utilization - In the reporting period, the company invested RMB 47.08 million in fundraising projects and permanently supplemented working capital with RMB 11.37 million [5] - By December 31, 2024, the total direct investment in fundraising projects reached RMB 66.09 million, with RMB 156.71 million used to replace self-raised funds [5][6] - The company has established a management system for fundraising, ensuring funds are stored in dedicated accounts and used according to strict approval procedures [6][28] Internal Control Evaluation - The company conducted an internal control evaluation as of December 31, 2024, concluding that there were no significant defects in financial reporting controls [13][41] - The internal control framework includes governance structures, risk assessment, and control activities across various operational areas, ensuring compliance with relevant laws and regulations [14][24][28] - The company has established a robust internal audit function to monitor compliance and effectiveness of internal controls [36] Profit Distribution Proposal - The board of directors approved a profit distribution proposal for 2024, recommending a cash dividend of RMB 1.80 per share, totaling approximately RMB 18.19 million [53][55] - The proposal is in line with the company's profit distribution policy and aims to provide reasonable returns to shareholders while ensuring the company's sustainable development [55][57] - The company has maintained a strong cash dividend history, exceeding the average net profit over the past three years [56]

数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1635 | 0.0828 | 97.46 | 0.3945 | | 每股净资产（元） | 0 | 15.39 | -100 | 16.83 | | 每股公积金(元) | 6.23 | 9.69 | -35.71 | 9.48 | | 每股未分配利润(元) | 3.45 | 5.21 | -33.78 | 5.86 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.96 | 1.83 | 7.1 | 2.01 | | 净利润(亿元) | 0.16 | 0.08 | 100 | 0.28 | | 净资产收益率(%) | | 0.77 | -100 | 2.37 | 本次公司不分配不转赠。 前十大流通股东累计持有： 571.2万股，累计占流通股比： 17.27%，较 ...

中信证券股份有限公司 进行现金管理事项的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）担任恩威 医药股份有限公司（以下简称"恩威医药"、"上市公司"或"公司"）首次公开 发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》等有关规定，对恩威医药使用部分闲置募集 资金与部分闲置自有资金进行现金管理事项发表核查意见如下： 一、本次募集资金的基本情况 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，每股面 值 1.00 元，发行价格为人民币 29.80 元/股。本次募集资金总额为人民币 522,692,000.00 元，扣除发行费用（不含增值税）人民币 79,741,650.79 元后，实 际募集资金净额为人民币 ...

恩威医药股份有限公司 2024年度 审计报告 | 索引 | | 页码 | | --- | --- | --- | | 审计报告 | | 1-5 | | 公司财务报告 | | | | — | 合并资产负债表 | 1-2 | | — | 母公司资产负债表 | 3-4 | | — | 合并利润表 | 5 | | — | 母公司利润表 | 6 | | — | 合并现金流量表 | 7 | | — | 母公司现金流量表 | 8 | | — | 合并所有者权益变动表 | 9-10 | | — | 母公司所有者权益变动表 | 11-12 | | — | 财务报表附注 | 13-90 | 审计报告 XYZH/2025CDAA3B0062 恩威医药股份有限公司 恩威医药股份有限公司全体股东： 一、审计意见 我们审计了恩威医药股份有限公司（以下简称恩威医药公司）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并及母公司利润表、合并及 母公司现金流量表、合并及母公司股东权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反 映了恩威医药 ...

恩威医药股份有限公司 2024 年 12 月 31 日 内部控制审计报告 索引 页码 内部控制审计报告 1-2 内部控制审计报告 XYZH/2025CDAA3B0064 恩威医药股份有限公司 恩威医药股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计 了恩威医药股份有限公司（以下简称恩威医药公司）2024年12月31日财务报告内部控制 的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是恩威医药公司董事 会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意 见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控 制审计结果推测未来内部控制的有效性具有一定风险。 1 审计报告（续） XYZH/2025CDAA3B0 ...

中信证券股份有限公司 关于恩威医药股份有限公司 单位：万元 | | | 关联交易类别：向关联人采购产品、商品 | | | | | --- | --- | --- | --- | --- | --- | | 关联人 | 关联交易内容 | 关联交 易定价 | 合同签订金额 或预计金额 | 截至披露日 已发生金额 | 年度已 2024 发生金额 | | | | 原则 | | | | | 吉林恩威锐 邦药业有限 | 头孢克肟分散片、 左氧氟沙星片、舒 | 市场价 | 500.00 | 455.36 | 0.00 | | 公司 | 筋丸等产品 | 格 | | | | 1 注：以上表格列示金额均为不含税金额，截至披露日已发生金额未经审计。 （三）上一年度日常关联交易实际发生情况 2025年度预计日常关联交易的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为恩威 医药股份有限公司（以下简称"恩威医药"或"公司"）首次公开发行股票并在 创业板上市的保荐机构（主承销商），根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》及《深圳证券交易所上市公司自律监管 指引第 2 号——创业板 ...

中信证券股份有限公司 关于恩威医药股份有限公司 2024年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为恩威 医药股份有限公司（以下简称"恩威医药"或"公司"）首次公开发行股票并在 创业板上市的保荐机构（主承销商），根据《证券发行上市保荐业务管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》等相关法律法规和规范性文件的要求，对公 司 2024 年度募集资金年度存放与使用情况进行了审慎核查，情况如下： 一、募集资金到位及基本使用情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，每股面 值 1.00 元，发行价格为人民币 29.80 元/股。本次募集资金总额为人民币 522,692,000.0 ...